Friday, May 29, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

CDC ‘starting to see mix-and-match data’ for COVID-19 vaccines

With the Pfizer (PFE)/BioNTech (BNTX) booster guidance in the rearview mirror, the CDC and the country’s other regulatory and public health agencies are gearing up to tackle Moderna’s (MRNA) and eventually Johnson & Johnson’s (JNJ) booster filings for recipients of those vaccines.

Meanwhile, many have wondered why the U.S. is not following Europe’s and Canada’s lead in allowing mixing and matching of vaccine brands in order to be considered fully vaccinated or for booster doses.

CDC Director Dr. Rochelle Walensky told that information is not too far away.

“We’re starting to see some of the mix-and-match data,” she said, noting that studies are already underway.

“As soon as we have those data to present, both to the FDA and to the CDC, we’ll have recommendations there as well,” Walensky said.

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), said Tuesday the first batch of data pertains to Moderna as a booster for either the J&J or Pfizer vaccines.

That data is available now, and data from trials of the other two vaccines as mixed boosters are forthcoming in the next month.

Source: Yahoo Finance

https://finance.yahoo.com/news/cdc-starting-to-see-mix-and-match-data-for-covid-19-vaccines-director-131034795.html

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!